BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation.

Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.

Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent’s success pushed Sanofi’s total net sales to €9.9bn, up 10% at ...

Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Director-general for WHO says leaders want self-reliance, with tobacco and alcohol tax rises on the cards to boost domestic revenue.

MetrioPharm’s lead compound, MP1032, has received ODD from the European Medicines Agency (EMA) for treating DMD in children.

Viridian and Kissei Pharmaceutical have signed an exclusive partnership and license agreement for advancing veligrotug and VRDN-003.

The Maryland Prescription Drug Affordability Board (PDAB) found that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) present affordability ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.